Toronto, Ontario, Canada--Theralase Technologies (TSX-V: TLT) has developed a new application for its photodynamic compounds (PDCs): the destruction of Listeria Monocytogenes, a widely prevalent disease-causing bacteria. Theralase uses lasers to activate PDCs intended to target and destroy cancers, bacteria, and viruses.
The Theralase PDCs have shown the ability to destroy bacteria in vitro when light-activated, according to new research performed at the Princess Margaret Hospital, University Health Network (UHN). Future applications of the PDC technology in bacteria destruction may involve sterilizing food-processing equipment, hospital treatment rooms, and medical equipment, and eliminating bacteria in wounds and other locations.
"We are encouraged that our photodynamic compounds are proving effective in many varied applications," said Roger Dumoulin-White, president and CEO of Theralase. "Not only are these PDCs being shown to be effective in the destruction of a variety of cancer cells in our ongoing research at Princess Margaret Hospital, but now they are also being shown to be effective in the destruction of bacteria. Commercialization of these technologies becomes more and more apparent as our research and development progresses."
Subscribe now to Laser Focus World magazine; it’s free!
